In contrast to F-18-flourodesoxyglucose (FDG) PET/CT, which has a limited sensitivity to detect ccRCC metastases, a prospective study of oligometastatic ccRCC patients showed that the PSMA-targeted tracer F-18-DCFPyL PET/CT detected more metastatic lesions than conventional imaging, including CT and MRI [10,11]. Here, FOLH1 is linked to nonpapillary renal cell carcinoma.